Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, W.
Right arrow Articles by Ratain, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, W.
Right arrow Articles by Ratain, M. J.
Clinical Cancer Research Vol. 9, 1009-1012, March 2003
© 2003 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Interethnic Difference in the Allelic Distribution of Human Epidermal Growth Factor Receptor Intron 1 Polymorphism1

Wanqing Liu, Federico Innocenti, Peixian Chen, Soma Das, Edwin H. Cook, Jr. and Mark J. Ratain2

Departments of Medicine [W. L., F. I., M. J. R.], Human Genetics [P. C., S. D., E. H. C.], and Psychiatry and Pediatrics [E. H. C.], Committee on Clinical Pharmacology and Pharmacogenomics [F. I., E. H. C., M. J. R.], and Cancer Research Center [F. I., M. J. R.], The University of Chicago, Chicago, Illinois 60637

Purpose: Epidermal growth factor receptor (EGFR) plays a critical role in signal transduction and is a target for a novel class of anticancer agents that aim to inhibit EGFR-mediated cancer cell growth. Previous studies have demonstrated a dinucleotide (CA)n repeat polymorphism in intron 1 of EGFR, ranging from 14 to 21 repeats, that has been suggested to regulate EGFR expression. The longer allele with 21 repeats showed an 80% reduction of gene expression compared with the shorter allele with 16 repeats. Therefore, the evaluation of the allelic distribution of this polymorphism in populations of various ethnic origins will be crucial to understand the interindividual variability in EGFR expression.

Experiment Design: We evaluated the influence of ethnicity on this polymorphism by genotyping individuals of Caucasian (n = 183), African-American (n = 84), and Asian (n = 66) background.

Results: The frequency of one of the longer alleles, allele 20 is significantly higher in Asian individuals (63% compared with 21% in Caucasians, P = 2 x 10-18). In confirmation of prior studies, the shorter allele 16 was the most common allele in Caucasians (43%) and African-Americans (42%), but its frequency was significantly lower in Asians (average 17%, P = 10-7 compared with Caucasians).

Conclusion: Major interethnic differences in the allelic frequencies of the EGFR intron 1 polymorphism exist. Our results may contribute to a better understanding of the molecular basis underlying ethnic differences in drug response and may be helpful for future strategies of individualized therapy with EGFR inhibitors.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
D. W. Bell, B. W. Brannigan, K. Matsuo, D. M. Finkelstein, R. Sordella, J. Settleman, T. Mitsudomi, and D. A. Haber
Increased Prevalence of EGFR-Mutant Lung Cancer in Women and in East Asian Populations: Analysis of Estrogen-Related Polymorphisms
Clin. Cancer Res., July 1, 2008; 14(13): 4079 - 4084.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
O. A. Press, W. Zhang, M. A. Gordon, D. Yang, G. Lurje, S. Iqbal, A. El-Khoueiry, and H.-J. Lenz
Gender-Related Survival Differences Associated with EGFR Polymorphisms in Metastatic Colon Cancer
Cancer Res., April 15, 2008; 68(8): 3037 - 3042.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Graziano, A. Ruzzo, F. Loupakis, E. Canestrari, D. Santini, V. Catalano, R. Bisonni, U. Torresi, I. Floriani, G. Schiavon, et al.
Pharmacogenetic Profiling for Cetuximab Plus Irinotecan Therapy in Patients With Refractory Advanced Colorectal Cancer
J. Clin. Oncol., March 20, 2008; 26(9): 1427 - 1434.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. Rudin, W. Liu, A. Desai, T. Karrison, X. Jiang, L. Janisch, S. Das, J. Ramirez, B. Poonkuzhali, E. Schuetz, et al.
Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity
J. Clin. Oncol., March 1, 2008; 26(7): 1119 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Liu, X. Wu, W. Zhang, R. C. Montenegro, D. L. Fackenthal, J. A. Spitz, L. M. Huff, F. Innocenti, S. Das, E. H. Cook, Jr., et al.
Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines
Clin. Cancer Res., November 15, 2007; 13(22): 6788 - 6795.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. V. Karamouzis, J. R. Grandis, and A. Argiris
Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas
JAMA, July 4, 2007; 298(1): 70 - 82.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti
Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response
Ann. Surg. Oncol., July 1, 2007; 14(7): 2150 - 2158.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K. Al-Kuraya, H. Novotny, P. Bavi, A. K Siraj, S. Uddin, A. Ezzat, N. A. Sanea, F. Al-Dayel, H. Al-Mana, S. S Sheikh, et al.
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer
J. Clin. Pathol., July 1, 2007; 60(7): 768 - 772.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Araujo, R. Ribeiro, I. Azevedo, A. Coelho, M. Soares, B. Sousa, D. Pinto, C. Lopes, R. Medeiros, and G. V. Scagliotti
Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature
Oncologist, February 1, 2007; 12(2): 201 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S-H. Ou, J. Zell, A Ziogas, and H Anton-Culver
Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology
Ann. Onc., January 1, 2007; 18(1): 29 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Brandt, S. Meyer-Staeckling, H. Schmidt, K. Agelopoulos, and H. Buerger
Mechanisms of egfr Gene Transcription Modulation: Relationship to Cancer Risk and Therapy Response
Clin. Cancer Res., December 15, 2006; 12(24): 7252 - 7260.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E.W. Cohen
Role of Epidermal Growth Factor Receptor Pathway-Targeted Therapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
J. Clin. Oncol., June 10, 2006; 24(17): 2659 - 2665.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Calvo and J. Baselga
Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
J. Clin. Oncol., May 10, 2006; 24(14): 2158 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. V. Sequist, D. A. Haber, and T. J. Lynch
Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: Predicting Clinical Response to Kinase Inhibitors
Clin. Cancer Res., August 15, 2005; 11(16): 5668 - 5670.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M.-C. Etienne-Grimaldi, S. Pereira, N. Magne, J.-L. Formento, M. Francoual, X. Fontana, F. Demard, O. Dassonville, G. Poissonnet, J. Santini, et al.
Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
Ann. Onc., June 1, 2005; 16(6): 934 - 941.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Giaccone
Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
J. Clin. Oncol., May 10, 2005; 23(14): 3235 - 3242.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Giaccone
HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy
Ann. Onc., April 1, 2005; 16(4): 538 - 548.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. R. Sellers and M. Meyerson
EGFR Gene Mutations: A Call for Global x Global Views of Cancer
J Natl Cancer Inst, March 2, 2005; 97(5): 326 - 328.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Liu, F. Innocenti, M. H. Wu, A. A. Desai, M. E. Dolan, E. H. Cook Jr., and M. J. Ratain
A Functional Common Polymorphism in a Sp1 Recognition Site of the Epidermal Growth Factor Receptor Gene Promoter
Cancer Res., January 1, 2005; 65(1): 46 - 53.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. T. Shah, M. G. Kris, W. Pao, L. B. Tyson, B. M. Pizzo, M.-H. Heinemann, L. Ben-Porat, D. L. Sachs, R. T. Heelan, and V. A. Miller
Practical Management of Patients With Non-Small-Cell Lung Cancer Treated With Gefitinib
J. Clin. Oncol., January 1, 2005; 23(1): 165 - 174.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. L. Amador, D. Oppenheimer, S. Perea, A. Maitra, G. Cusati, C. Iacobuzio-Donahue, S. D. Baker, R. Ashfaq, C. Takimoto, A. Forastiere, et al.
An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors
Cancer Res., December 15, 2004; 64(24): 9139 - 9143.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Shuch, M. Mikhail, J. Satagopan, P. Lee, H. Yee, C. Chang, C. Cordon-Cardo, S. S. Taneja, and I. Osman
Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer
J. Clin. Oncol., December 1, 2004; 22(23): 4725 - 4729.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarwala, and L. L. Siu
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
J. Clin. Oncol., January 1, 2004; 22(1): 77 - 85.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Brandt, S. Hermann, K. Straif, N. Tidow, H. Buerger, and J. Chang-Claude
Modification of Breast Cancer Risk in Young Women by a Polymorphic Sequence in the egfr Gene
Cancer Res., January 1, 2004; 64(1): 7 - 12.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2003 by the American Association for Cancer Research.